William Blair Reiterates an 'Outperform' on Dynavax (DVAX); Heplisav VRBPAC Panel Set - What to Watch For
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/15/2026
- S&P 500 and Nasdaq end higher on cool inflation data, solid bank earnings
- IBM plunges 19% as memory capex squeeze derails Q2 earnings
- Fed’s Warsh says central bank won’t tolerate high inflation
- Software stocks tumble: High memory prices cannibalize enterprise tech capex
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
- IBM misses Q2 targets as mainframe and software sales disappoint
- Verizon planning new round of layoffs this week - Barron’s
- S&P 500 and Nasdaq end higher on cool inflation data, solid bank earnings
- Lucid Group shares quickly cut in half on report of potential bankruptcy
- HSBC Downgrades IBM (IBM) to Reduce, 'Stretched Valuation'
Jefferies Maintains a 'Buy' on Dynavax Technologies (DVAX); Next Catalyst For Heplisav
August 29, 2012 7:33 AM EDTJefferies maintains a 'Buy' on Dynavax Technologies (NASDAQ: DVAX) price target of $6.00.
Analyst, Thomas Wei, said, "DVAX announced that an FDA advisory committee meeting for Heplisav will be held on November 14-15, in advance of its February 24 action date. We continue to believe... More
Dynavax (DVAX) Announces November 14-15 FDA AdCom for HEPLISAV
August 28, 2012 9:07 AM EDTDynavax Technologies Corporation (NASDAQ: DVAX) said the FDA informed the Company that its Vaccines and Related Biological Products Advisory Committee (VRBPAC) is scheduled to discuss HEPLISAV at its meeting on November 14-15, 2012.
Dynavax's Biologic License Application (BLA) for HEPLISAV, pursuing an indication for... More
